Orthopaedic review of BPC-157 finds the human evidence is still a footnote

A systematic review in the orthopaedic sports-medicine literature tried to do the unglamorous job that individual lab papers skip: count what is actually there. Reviewers searched PubMed, Cochrane, and Embase from inception through June 3, 2024, screened 544 records, and included 36 studies. Thirty-five were preclinical. One was clinical.

What the preclinical set reports

Across muscle, tendon, ligament, and bone models, the included animal and cell studies are summarized as showing better functional, structural, or biomechanical recovery after injury, alongside signals the authors group under growth-hormone-receptor expression, angiogenesis-related pathways, and lower inflammatory cytokines. Those are the claims that travel fastest into marketing. They are also claims from injury models, not from randomized patients.

What the clinical set actually is

The lone clinical item was a retrospective series of intra-articular injections for unspecified chronic knee pain. Seven of twelve patients were described as reporting relief for more than six months. There was no control arm. A dozen charts cannot establish efficacy, dose, or safety.

Safety, sport, and approval

The review states that BPC-157 is not FDA-approved and notes that it is banned in professional sport. On disposition, the authors report hepatic metabolism, renal clearance, and a half-life under 30 minutes, drawn from non-clinical work. They also say they found no clinical safety data set. Their own conclusion stays at level IV and V evidence: animal results can look favorable while unregulated manufacturing, contamination, and unknown human safety remain open.

That is the news. A fresh review did not discover a hidden phase 3 program. It documented how thin the human record still is. Nothing in that count is a reason to buy a research vial.